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S U M M A R Y
Objectives: The natural history of blood donors infected with human T-lymphotropic virus type 1 (HTLV-
1) in Israel has never been assessed. The aim of this study was to evaluate the prevalence of malignant
disorders and mortality among a cohort of Israelis diagnosed as HTLV-1 carriers during routine blood
unit screening.
Methods: This was an observational retrospective cohort study. All HTLV-1 cases among Israeli blood
donors between 1995 and 2009 were included. Data regarding malignant diseases were extracted from
the Israel National Cancer Registry. Mortality data were extracted from the Israel Population Registry.
Results: Between January 9, 1995 and December 31, 2009, 1 574 497 blood donors were screened for
HTLV-1 in the central blood bank services. Of these, 90 were found to be HTLV-1 carriers. This cohort of
HTLV-1-infected blood donors was followed for an average of 9.2  6 years. Among them six (6.7%) were
diagnosed as having malignant diseases, four of them with adult T-cell leukemia/lymphoma (ATLL). The
incidence of ATLL was 0.37 (95% conﬁdence interval 0.13–1.08)/100 HTLV-1 carrier-years.
Conclusions: We found a high rate of malignant diseases among HTLV-1-infected blood donors.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Human T-cell lymphotropic virus type 1 (HTLV-1) is prevalent
mostly in Japan, Africa, the Caribbean islands, South America, and
parts of Oceania (Papua New Guinea, the Solomon Islands, and
Vanuatu).1–3 Known modes of transmission of HTLV-1 include:
vertical transmission, predominantly through breastfeeding and
mainly when newborns are breastfed for more than 3–6 months;
and horizontal transmission, through sexual intercourse, transfu-
sion of infected cellular blood products, and sharing of needles and
syringes.1–3
HTLV-1 was the ﬁrst retrovirus linked to human disease. It is
estimated that 10–20 million people worldwide are infected with
HTLV-1. Although the majority of infected people remain asymptom-
atic, the virus is associated with exceptionally severe diseases. It has
been convincingly associated with adult T-cell leukemia/lymphoma* Corresponding author. Tel.: +972 52 6666131; fax: +972 3 5535953.
E-mail addresses: sshmuel@netvision.net.il,
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(HAM/TSP), and uveitis. HTLV-1 has also been linked, without
convincing proof, to cases of polymyositis, synovitis, thyroiditis,
infective dermatitis, Sjo¨gren’s syndrome, arthropathy, polyneuro-
pathy, T-lymphocyte alveolitis, and cutaneous T-cell lymphoma. In
addition, several infections such as strongyloidiasis, scabies, leprosy,
and tuberculosis  have been associated with HTLV-1.1,2
Among HTLV-1 carriers, the lifetime risk of developing HTLV-1-
associated diseases in general, including ATLL, HAM/TSP, uveitis,
polymyositis, and arthropathy, may be close to 10%.1
The screening of all blood units for HTLV-1 antibodies was
instituted in Israel in 1995. The prevalence of HTLV-1 infection
among blood donors in Israel was found to be in the range of 1/
100 000 in Israeli-born donors to 20.4 per 100 000 among donors
originating from Latin America, Iran, Romania, and the former
Soviet Union.4
The frequency of malignant diseases in blood donors infected
with HTLV-1 in Israel, and their mortality, has never been assessed.
The aim of this study was to evaluate the prevalence of malignant
disorders and mortality among a cohort of Israelis diagnosed as
HTLV-1 carriers during routine blood unit screening.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Summary of malignant diseases in Israeli blood donors infected with HTLV-1
Gender Country of origin Died Disease Age at HTLV carrier
state diagnosis, years
Age at malignant disease
diagnosis, years
Male Islamic Republic of Iran Yes Adult T-cell leukemia/lymphoma 55 58
Female Romania Yes Adult T-cell leukemia/lymphoma 31 35
Male Iraq Yes Adult T-cell leukemia/lymphoma 47 50
Male Niger No Mycosis fungoides 55 64
Female Islamic Republic of Iran No Cervical carcinoma 62 31
Male Chile No Transitional cell carcinoma 42 51
HTLV-1, human T-lymphotropic virus type 1.
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We conducted a nationwide study looking at the incidence of
ATLL in all blood donors who were diagnosed as HTLV-1 carriers.
Blood donation in Israel is voluntary and does not involve any
ﬁnancial beneﬁt. All blood units donated in Israel are processed in
the central blood services of Magen David Adom. We registered the
Israeli identiﬁcation number, age, gender, donor country of birth,
maternal country of birth, and paternal country of birth once for
each HTLV-1-infected donor, regardless of the number of blood
units donated.
Through the years 1995–1998 all donors were screened for
anti-HTLV-1/2 antibodies using a standard ELISA with the Abbott
HTLV-1/HTLV-2 EIA. Since 1998 testing has been performed with a
ChLIA (chemiluminescent immunoassay; PRISMTM, Abbott). A
conﬁrmatory Western blot assay (Genelabs Diagnostics HTLV Blot
2.4) was done on all samples with a positive ELISA/ChLIA result.
On the basis of virus transmission modes, we developed an
algorithm for identifying the ethnic origin of both HTLV-1-positive
and HTLV-1-negative blood donors. We considered infection to
have been acquired in Israel when the donor and both parents were
born in Israel. We considered the infection to have been acquired
outside Israel when the donor or one parent was born outside
Israel. When the donor was born in Israel and the mother was born
outside Israel, the country of origin was considered the mother’s
country of birth. When the donor and the mother were born in
Israel, but the father was born outside Israel, the country of origin
was considered the father’s country of birth.
Every citizen in Israel is identiﬁed by a unique identiﬁcation
number given at birth, or during naturalization. The Israel
Population Registry identiﬁes every citizen by this identiﬁcation
number. All deaths in Israel are reported to the Israel Population
Registry. The reporting of malignant diseases is obligatory in Israel.
The patients with malignant diseases are reported to the Israel
National Cancer Registry. Data regarding morbidity with malig-
nant diseases were extracted from the Israel National Cancer
Registry. Data regarding mortality and the date of death were
extracted from the Israel Population Registry.
Age is expressed as the mean  standard deviation. Proportions
are expressed with the 95% conﬁdence interval (95% CI).
The study was approved by the Chaim Sheba Medical Center
Human Subject Research Review Board. No ﬁnancial support for
was given for this research.
3. Results
From January 9, 1995, through December 31, 2009, 1 574 497
blood donors were screened for HTLV-1 infection; 72% of them
were males. Of these blood donors, 90 were identiﬁed as being
HTLV-1 carriers. The average age at diagnosis of the HTLV-1 carrier
state was 39.98  12.54 years; 52 (58%) were men. The HTLV-1
carrier blood donors were followed for an average of 9.2  6 years
(range 0.5–14.6 years). The average age of HTLV-1 carriers at the time
of the data analysis was 50.2  13.0 years.Among these carriers, six (6.7%) were diagnosed as having a
malignant disease (see Table 1); four (66.7%) were males. The
average age at diagnosis of the malignant disease was 48.2  12.9
years. None of the HTLV-1 blood donors who developed a malignancy
were of Israeli origin.
Of the patients with a malignant neoplasm, four (66%) had a T-
cell lymphoma (three with ATLL and one with mycosis fungoides)
and two had carcinoma (Table 1). The incidence of ATLL was 0.37
(95% CI 0.13–1.08)/100 HTLV-1 carrier-years.
Three of the patients died (50%), all of them suffering from ATLL.
Two of the patients died within 2 months of diagnosis and the third
survived for almost 3 years. The cumulative death rate was 3.3%
(95% CI 1.1–9.3%). No death was recorded during the study period
among HTLV-1 carriers without malignancy.
4. Discussion
Among HTLV-1 carriers, the lifetime risk of developing HTLV-1-
associated diseases in general, including ATLL, HAM/TSP, uveitis,
polymyositis, and arthropathy, may be close to 10%.1 The risk of
developing these complications depends on several factors,
including age and the route of infection, and is not uniform across
geographical areas.1 For example, in Japan, the annual incidence of
ATLL is 86 cases/100 000 among the general population, with a
peak around the age of 60 years, and is three times higher in men
than in women. In the Caribbean, the annual incidence is
approximately 20 cases/100 000, with little evidence of a male
predominance and with a peak around age 40 years.5
However, the lifetime risk of an HTLV-1 carrier developing T-
cell lymphoma is not well established. We found that 6.7% of HTLV-
1-positive blood donors developed a malignant disease during 10
years of follow-up.
In a review of the literature, we found only three studies that
tried to look at the prevalence of malignancy, most of them ATLL, in
cohorts of blood donors infected with HTLV-1. The prevalence of
ATLL in American HTLV-1 carrier blood donors was 0–2.7%6–8
(Table 2).
Another study9 that investigated HTLV-1 and HTLV-2 malig-
nancy-related mortality, found that 0.5% of HTLV-1 carrier blood
donors died of leukemia.
We found a higher rate (6.7%) of malignant diseases in Israeli
HTLV-1 carriers among blood donors. Even taking into account
only patients with T-cell lymphoma or ATLL, the percentages of
those diseases were 4.4% and 3.3%, respectively, which are higher
than published elsewhere. We feel that the difference between
our results and those published in the literature could be
explained by the longer follow-up period in the present study
than in previous reports, and the older age of the HTLV-1 carrier
blood donors in this study. Age is a well-known factor that is
associated with an increased risk of HTLV-1-associated ATLL. The
limitations of our study include the fact that we were unable to
review the pathology of the HTLV-1 blood donors with malignancy
and the lack of a national registry for other HTLV-1-associated
diseases.
Table 2
Frequencies of T-cell lymphoma in HTLV-positive blood donors
Population Positive donors, n Donors with T-cell
lymphoma, n (%)
Average age of HTLV-1
carriers, years
Follow-up, years Ref.
Blood donors, Israel 90 4 (4.4)a,b 50.2 10 Present study
Blood donors, USA 111 3 (2.7)c 45 2 6
Blood donors, USA 154 0 (0)d NA 4 7
Blood donors, Japan 3991 5 (0.12)e NA 2.7 8
NA, not available; ATLL, adult T-cell leukemia/lymphoma.
a Three cases of ATLL, one case of mycosis fungoides.
b Two more cases of carcinoma.
c All of them ATLL (only hematologic malignancies were screened).
d Two cases of cancer (no details provided).
e Two cases of B-cell lymphoma, three cases of other cancer (no details provided).
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suffered from mycosis fungoides, cervical carcinoma, and transi-
tional cell carcinoma, respectively. The link between mycosis
fungoides and HTLV-1 is controversial. A study among American
patients with mycosis fungoides showed that about two-thirds
appeared to be infected with HTLV-1 or HTLV-2 when analyzed by
PCR.10 Partially deleted HTLV-1 provirus has been found in
cutaneous lesions of patients with mycosis fungoides.11 However,
all serological surveys have failed to ﬁnd a link between mycosis
fungoides and HTLV-1 infection.12–15
Cancer of the uterine cervix is caused by the human
papillomavirus (HPV).16,17 HTLV-1 may act as an HPV-enhancing
cofactor by interfering with general immune function. A study in
Japan found a signiﬁcant association of HTLV-1 with cervical
cancer,18 and a pilot study conducted in Jamaica19 (a country with
high rates of cervical cancer) of sequential colposcopy, showed
elevated rates of HTLV-1 infection among subjects with cancer or
cervical intraepithelial neoplasia stage 3 in comparison with
subjects who had cervical intraepithelial neoplasia stage 1 or more
benign pathological conditions. A subsequent study done by the
same authors failed to show the same link.20
No study was found in the literature connecting HTLV-1
infection and transitional cell carcinoma.
Therefore, the incidence of ATLL in our HTLV-1 carrier blood
donors was 0.37 per 100 HTLV-1 carrier-years.
A study from Japan21 that followed 500 HTLV-1 carriers
suggested that they have an increased all-cause mortality risk,
even after excluding ATLL-related deaths. Other HTLV-1-associat-
ed illnesses were not among the diseases that caused death in the
HTLV-1 carriers. We did not ﬁnd any non-cancer-related deaths in
our cohort during the study period. However, the relatively small
sample (90 patients) in our study could account for this difference.
Because of the small size of our cohort, the present study does
not allow the determination of the yearly or lifetime risk of an
HTLV-1 carrier developing a malignant disorder. However, the
results suggest that a similar analysis with a larger cohort of HTLV-
1 carriers may provide more deﬁnite results. The results from this
small cohort demonstrate the need for closer clinical and
laboratory follow-up of such carriers.
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